We need all chances on our side
In the forests and fractured communities of Congo and Uganda, a strain of Ebola for which no vaccine or proven treatment yet exists has claimed more than 200 lives in just over a month. Science is responding with rare coordination — three vaccine platforms and multiple treatment candidates advancing simultaneously — yet history reminds us that speed in the laboratory does not always translate to control in the field. The true scale of this outbreak remains hidden in the silence of remote places and broken health systems, where the distance between a sick person and an official record can be the distance between a counted life and an uncounted one.
- The Bundibugyo Ebola strain has killed over 200 people and infected at least 875 across Congo and Uganda in barely a month, with experts warning the real toll is almost certainly far higher.
- No licensed vaccine or proven treatment exists for this specific strain, leaving health workers and communities exposed to a virus that kills with brutal speed.
- Three vaccine candidates — built on rVSV, ChAdOx1, and mRNA platforms — are racing forward in parallel, with some potentially entering human trials as early as July, while the WHO has flagged remdesivir and other antivirals for urgent testing.
- CEPI is funding all three vaccine bets at once, a deliberate strategy to maximize odds when no one yet knows which platform will succeed against this strain.
- History casts a long shadow: during the 2018 Zaire Ebola outbreak, doses were ready within 72 hours yet the crisis took two years to contain, a reminder that scientific readiness and on-the-ground control are two very different things.
- The outbreak's true reach remains unknown — spreading through conflict zones and remote villages where cases go unreported and the dead are buried without official count.
More than 875 confirmed cases and at least 202 deaths have been recorded across Congo and Uganda in just over a month, but those numbers almost certainly undercount the real toll. Bundibugyo Ebola is spreading through remote communities and conflict-affected regions where the sick cannot reach clinics and the dead are buried without official record. No vaccine exists for this strain. No treatment has been proven against it.
What does exist is an unusually coordinated scientific response. Three vaccine candidates are advancing simultaneously on different technological platforms: an adapted rVSV vector — the same backbone as the only licensed Ebola vaccine, which targets a different strain — is being refined by researchers including virologist Thomas Geisbert, with human trials potentially seven to nine months away. Oxford and the Serum Institute of India are developing a ChAdOx1-based vaccine, the same platform used for AstraZeneca's COVID-19 shot. Moderna is applying its mRNA technology to the problem. Both the Oxford and Moderna candidates could enter phase 1 trials within two to three months, possibly by July.
The Coalition for Epidemic Preparedness Innovations is funding all three simultaneously — a deliberate strategy of placing multiple bets rather than waiting to identify a frontrunner. 'We need all chances on our side,' said CEPI deputy CEO Aurelia Nguyen. On the treatment side, the WHO has identified remdesivir — the antiviral used during COVID-19 — and other candidates for urgent trials.
Yet Nguyen also offered a sobering counterweight to the optimism of rapid development. During the 2018 Zaire Ebola outbreak, vaccine doses were ready to ship within 72 hours. The outbreak still took two years to end. The gap between a vaccine in a vial and a virus under control is filled with the harder work of trust, access, and infrastructure — precisely the things most absent in the places where Bundibugyo is spreading now.
More than 875 cases of Bundibugyo Ebola have been confirmed across Congo and Uganda in just over a month, with at least 202 deaths recorded. The true toll is almost certainly higher. Humanitarian organizations warn that the virus continues spreading through remote areas, poor communities, and regions fractured by conflict—places where cases go unreported, where the sick cannot reach clinics, where the dead are buried without official count.
There is no vaccine for this strain. There is no proven treatment. What exists instead is urgency: a coordinated push by scientists, pharmaceutical manufacturers, and international funding bodies to develop both weapons against a virus that kills with brutal speed.
Three vaccine candidates are moving forward simultaneously, each built on a different technological platform. The first is based on rVSV, a modified virus vector that has already proven itself in the only licensed Ebola vaccine currently in use—though that vaccine targets the Zaire strain, not Bundibugyo. Scientists have now adapted it to match this outbreak's genetic signature. Thomas Geisbert, a virologist at the University of Texas Medical Branch who developed both rVSV vaccines, estimates the work could be compressed into six or seven months, though the World Health Organization's official timeline runs seven to nine months before human testing can begin.
The second candidate uses ChAdOx1, the same platform that underpinned AstraZeneca's COVID-19 vaccine. The University of Oxford is developing it in partnership with the Serum Institute of India, the world's largest vaccine manufacturer by volume. The third comes from Moderna, the American company that built its reputation on mRNA technology during the pandemic. Both the Oxford and Moderna vaccines could enter phase 1 human trials within two to three months—possibly as early as July, according to the Coalition for Epidemic Preparedness Innovations, a nonprofit that funds vaccine development and has pledged millions to support all three candidates.
Aurelia Nguyen, CEPI's deputy CEO, described the strategy as placing "three bets" on platforms with different strengths and different vulnerabilities. No one yet knows which will work. The point is to maximize the odds by pursuing all of them at once. "We need all chances on our side," she said.
But speed alone is not enough. Nguyen also noted a sobering historical fact: during the 2018 Zaire Ebola outbreak in Congo and Uganda, vaccine doses were ready to ship within 72 hours. It still took two years to bring that outbreak under control. The virus had time to spread, to find new hosts, to entrench itself in communities where trust in health systems was already fractured.
Beyond vaccines, the WHO has identified three treatments for urgent trial. One is remdesivir, an antiviral developed by Gilead that saw use against COVID-19. Others are being evaluated in parallel. The logic is the same: develop multiple approaches, test them quickly, hope that at least one proves effective enough to save lives.
What remains unknown is the true scale of what is happening on the ground. The 875 confirmed cases and 202 deaths are the cases that reached a clinic, that were tested, that entered an official record. In the places where Bundibugyo is spreading—remote villages, conflict zones, areas with minimal health infrastructure—the real numbers are almost certainly much larger. That gap between the known and the unknown is where the race against this virus is really being lost and won.
Citações Notáveis
This could be accelerated to six or seven months— Thomas Geisbert, virologist at University of Texas Medical Branch, on timeline for rVSV vaccine development
We need all chances on our side— Aurelia Nguyen, deputy CEO of CEPI, on the strategy of pursuing three vaccine platforms simultaneously
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that there are three different vaccine platforms in development instead of just one?
Because no one knows which one will work. They're all built on proven technology, but adapting them to a new virus is not guaranteed. By pursuing all three, you're hedging against the possibility that one fails or proves too slow to manufacture at scale.
The article mentions that a 2018 outbreak took two years to control even though vaccines were ready in 72 hours. What does that tell us?
It tells us that speed in the lab is not the same as speed in the field. Getting a vaccine made is one problem. Getting it to people in remote areas, building trust, actually vaccinating enough people to stop transmission—that's a different, harder problem. Two years suggests the virus had a lot of room to spread before the response caught up.
What's the significance of the Serum Institute of India being involved?
They're the world's largest vaccine manufacturer. If any of these candidates works, you need to be able to make millions of doses quickly. Having them at the table from the beginning means the moment a vaccine is approved, there's already manufacturing capacity ready to scale up.
Why is the true outbreak scale unknown?
Because the virus is spreading in places without reliable reporting systems—remote villages, conflict zones, areas where people can't or won't reach health clinics. The 875 cases are the ones that got tested and counted. The actual number of infections is almost certainly much higher.
If remdesivir was used for COVID, why isn't it already proven for Ebola?
Different viruses, different disease mechanisms. Something that works against one virus doesn't automatically work against another. They have to test it specifically for Bundibugyo to know if it's effective.